Do you want to read an article? Please log in or register.
Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma
Lymphoma
Related content
RECOMMENDED
Central Nervous System Tumors
Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Acta Neuropathol Commun
Hickman RA, Miller AM, Holle BM, Jee J, Liu SY, Ross D, Yu H, Riely GJ, Ombres C, Gewirtz AN, Reiner AS, Nandakumar S, Price A, Kaley TJ, Graham MS, Vanderbilt C, Rana S, Hill K, Chabot K, Campos C, Nafa K, Shukla N, Karajannis M, Li B, Berger M, Ladanyi M, Pentsova E, Boire A, Brannon AR, Bale T, Mellinghoff IK, Arcila ME
doi: 10.1186/s40478-024-01846-4
Further Publications
Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis
Ann Oncol
Valenza C, Saldanha EF, Gong Y, De Placido P, Gritsch D, Ortiz H, Trapani D, Conforti F, Cremolini C, Peters S, Mateo J, Subbiah V, Parsons HA, Partridge AH, Curigliano G
doi: 10.1016/j.annonc.2025.03.019
Lymphoma
PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study
Leuk Lymphoma
Jin J, Meng DD, Wen Y, Zhang QL, Lv FF, Chen GL, Ma XJ, Yu BH, Zhang SJ, Liu C, Xia ZG
doi: 10.1080/10428194.2024.2447888
Lymphoma
Clozapine is associated with an increased risk of Hodgkin and non-Hodgkin lymphoma
Leuk Lymphoma
Frey C, Etminan M
doi: 10.1080/10428194.2025.2461663
Lymphoma
A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk Stratification
Blood
Scarisbrick JJ, Quaglino P, Whittaker SJ, Bagot M, Guenova E, Papadavid E, Prince HM, Sanches JA, Miyashiro D, Servitje O, Querfeld C, Akilov OE, Arumainathan A, Bennett L, Battistella M, Benstead K Dr, Berti EF, Beylot-Barry M, Busschots AM, Cowan RA, Dummer R, Dunnill G, Estrach MT, Evison F, Bashir AE, Geskin LJ, Gru A, Guitart J, Herrera MC, Hodak E, Horwitz SM, Jonak C, Klemke CD, Knobler R, McKay P, Marschalkó M, Massone C, Matin R, Mitteldorf C, Novoa RA, Ortiz-Romero PL, Pimpinelli N, Pujol RM, Ranki A, Vankeva L, Rieger KE, Stadler R, Trautinger F, Latzka J, Vermeer MH, Wachsmuth R, Weatherhead S, Wehkamp U, Wobser M, Kim YH
doi: 10.1182/blood.2025029628
Multiple Myeloma (MM)
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis
Blood Cancer J
Martello M, Solli V, Mazzocchetti G, Solimando AG, Bezzi D, Taurisano B, Kanapari A, Poletti A, Borsi E, Armuzzi S, Vigliotta I, Pistis I, Desantis V, Marzocchi G, Rizzello I, Pantani L, Mancuso K, Tacchetti P, Testoni N, Nanni C, Zamagni E, Cavo M, Terragna C
doi: 10.1038/s41408-024-01185-6
Gynecologic Cancer
Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses
Ann Oncol
Mayadev J, Vázquez Limón JC, Ramírez Godinez FJ, Leiva M, Cetina-Pérez LDC, Varga S, Molina Alavez A, Alarcon-Rozas AE, Valdiviezo N, Acevedo C, Figueroa A, Santini A, Vera L, Rey F, Kahán Z, Galaz P, Meléndez Mier G, Wu X, Mandai M, Shapira-Frommer R, Estevez-Diz MDP, Limaye S, Xin W, Dry H, Broggi MAS, Yuan DY, Stewart RA, Monk BJ
doi: 10.1016/j.annonc.2025.05.533
Gastrointestinal Cancer
Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials
J Clin Oncol
Taieb J, Souglakos J, Boukovinas I, Falcoz A, Pages F, Messaritakis I, Bennouna J, Artru P, Louvet C, Lepere C, Emile JF, Bouche O, Mazard T, Vernerey D, Vogiatzoglou K, Tzardi M, Sharma S, Liu MC, Sethi H, André T, Galon J, Laurent-Puig P
doi: 10.1200/JCO.24.00648
Breast Cancer
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
Ann Oncol
André F, Solovieff N, Su F, Bardia A, Neven P, Yap YS, Tripathy D, Lu YS, Slamon D, Chia S, Joshi M, Chakravartty A, Lteif A, Taran T, Arteaga CL
doi: 10.1016/j.annonc.2024.09.010